BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 30072579)

  • 1. Glycomic Profiling Highlights Increased Fucosylation in Pseudomyxoma Peritonei.
    Saarinen L; Nummela P; Leinonen H; Heiskanen A; Thiel A; Haglund C; Lepistö A; Satomaa T; Hautaniemi S; Ristimäki A
    Mol Cell Proteomics; 2018 Nov; 17(11):2107-2118. PubMed ID: 30072579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Altered linkage pattern of N-glycan sialic acids in pseudomyxoma peritonei.
    Nummela P; Heiskanen A; Kytölä S; Haglund C; Lepistö A; Satomaa T; Ristimäki A
    Glycobiology; 2021 Apr; 31(3):211-222. PubMed ID: 33539510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis.
    Semino-Mora C; Liu H; McAvoy T; Nieroda C; Studeman K; Sardi A; Dubois A
    Ann Surg Oncol; 2008 May; 15(5):1414-23. PubMed ID: 18299935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pseudomyxoma peritonei is a disease of MUC2-expressing goblet cells.
    O'Connell JT; Tomlinson JS; Roberts AA; McGonigle KF; Barsky SH
    Am J Pathol; 2002 Aug; 161(2):551-64. PubMed ID: 12163380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy.
    Gleeson EM; Feldman R; Mapow BL; Mackovick LT; Ward KM; Morano WF; Rubin RR; Bowne WB
    Am J Clin Oncol; 2018 Aug; 41(8):777-783. PubMed ID: 28263231
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei.
    Akashi S; Kuwabara H; Yasuda E; Akutagawa H; Takeshita A; Kurisu Y; Egashira Y; Hirose Y; Yuki M; Tsuda Y; Hayashi M
    Diagn Cytopathol; 2016 Jul; 44(7):628-31. PubMed ID: 27079739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-glycosylation Profiling of Colorectal Cancer Cell Lines Reveals Association of Fucosylation with Differentiation and Caudal Type Homebox 1 (CDX1)/Villin mRNA Expression.
    Holst S; Deuss AJ; van Pelt GW; van Vliet SJ; Garcia-Vallejo JJ; Koeleman CA; Deelder AM; Mesker WE; Tollenaar RA; Rombouts Y; Wuhrer M
    Mol Cell Proteomics; 2016 Jan; 15(1):124-40. PubMed ID: 26537799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei.
    Noguchi R; Yano H; Gohda Y; Suda R; Igari T; Ohta Y; Yamashita N; Yamaguchi K; Terakado Y; Ikenoue T; Furukawa Y
    Cancer Med; 2015 Dec; 4(12):1809-16. PubMed ID: 26475379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei.
    Choudry HA; Mavanur A; O'Malley ME; Zeh HJ; Guo Z; Bartlett DL
    Ann Surg Oncol; 2012 May; 19(5):1402-9. PubMed ID: 22302271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC2 is a molecular marker for pseudomyxoma peritonei.
    O'Connell JT; Hacker CM; Barsky SH
    Mod Pathol; 2002 Sep; 15(9):958-72. PubMed ID: 12218214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A specific cadherin phenotype may characterise the disseminating yet non-metastatic behaviour of pseudomyxoma peritonei.
    Bibi R; Pranesh N; Saunders MP; Wilson MS; O'dwyer ST; Stern PL; Renehan AG
    Br J Cancer; 2006 Nov; 95(9):1258-64. PubMed ID: 17031402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multiple components of PKA and TGF-β pathways are mutated in pseudomyxoma peritonei.
    Saarinen L; Nummela P; Thiel A; Lehtonen R; Järvinen P; Järvinen H; Aaltonen LA; Lepistö A; Hautaniemi S; Ristimäki A
    PLoS One; 2017; 12(4):e0174898. PubMed ID: 28426742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secreted mucins in pseudomyxoma peritonei: pathophysiological significance and potential therapeutic prospects.
    Amini A; Masoumi-Moghaddam S; Ehteda A; Morris DL
    Orphanet J Rare Dis; 2014 May; 9():71. PubMed ID: 24886459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Arising from Urachus.
    Liu Y; Ishibashi H; Hirano M; Takeshita K; Mizumoto A; Ichinose M; Nishino E; Kashu I; Yamamoto Y; Sugarbaker PH; Yonemura Y
    Ann Surg Oncol; 2015 Aug; 22(8):2799-805. PubMed ID: 25572681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting hypoxia-mediated mucin 2 production as a therapeutic strategy for mucinous tumors.
    Dilly AK; Lee YJ; Zeh HJ; Guo ZS; Bartlett DL; Choudry HA
    Transl Res; 2016 Mar; 169():19-30.e1. PubMed ID: 26589109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathological prognostic factors of pseudomyxoma peritonei: comprehensive clinicopathological analysis of 155 cases.
    Yan F; Lin Y; Zhou Q; Chang H; Li Y
    Hum Pathol; 2020 Mar; 97():9-18. PubMed ID: 31926211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ovarian mature teratomas with mucinous epithelial neoplasms: morphologic heterogeneity and association with pseudomyxoma peritonei.
    McKenney JK; Soslow RA; Longacre TA
    Am J Surg Pathol; 2008 May; 32(5):645-55. PubMed ID: 18344868
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mucinous tumors arising in ovarian mature cystic teratomas: relationship to the clinical syndrome of pseudomyxoma peritonei.
    Ronnett BM; Seidman JD
    Am J Surg Pathol; 2003 May; 27(5):650-7. PubMed ID: 12717249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mitogen-activated protein kinase inhibition reduces mucin 2 production and mucinous tumor growth.
    Dilly AK; Song X; Zeh HJ; Guo ZS; Lee YJ; Bartlett DL; Choudry HA
    Transl Res; 2015 Oct; 166(4):344-54. PubMed ID: 25890193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment.
    Kuracha MR; Thomas P; Loggie BW; Govindarajan V
    Cancer Med; 2016 Apr; 5(4):711-9. PubMed ID: 26833741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.